The USA’s comprehensive strategy for HIV/AIDS prevention and treatment.
Topic(s): Normative Guidance/Policies
Product(s): Oral PrEP
Region(s): North America
Format(s): Country Landscape Analysis, Report
Countries: United States
Source(s): White House ONAP
Type: Document
This plan, developed by Nigeria’s Federal Ministry of Health and Social Welfare and National Agency for the Control of AIDS, provides a roadmap for reversing the HIV epidemic in Nigeria.
This National HIV Prevention Roadmap 2026-2028 outlines Ghana’s HIV and AIDS prevention measures which are based on the five core prevention pillars -Adolescent Girls and Young Women, Adolescent Boys and Young Men, Vulnerable Populations, Condoms, and Anti-Retroviral based Prevention.
These clinical guidelines, developed by Mozambique’s Ministry of Health in 2025, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
These clinical guidelines, developed by Lesotho’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
These implementation guidelines, developed by Eswatini’s Ministry of Health in 2025, can be used to support delivery of PrEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
These clinical guidelines, developed by Kenya’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
Last update: April 2026 Visit data.prepwatch.org for a dynamic map-based tool to explore trends in PrEP use globally, including by country, product, and time period. Comprehensive datasets are available to download by clicking “download data” in the upper righthand corner. For any questions, contact [email protected]. Introduction to the Global PrEP Tracker
This website, developed and maintained by the University of Liverpool, provides clear, trustworthy, and up-to-date information about how different PrEP options, including oral PrEP, cabotegravir, lenacapavir, and the dapivirine vaginal ring, can interact with other drugs.
These materials, developed by Zambia’s Ministry of Health, can be used to train clinicians and mobilisers in delivery of PrEP methods, including injectable lenacapavir (LEN), cabotegravir (CAB), the dapivirine vaginal ring (DVR), the Dual Prevention Pill (DPP), and oral PrEP.
These clinical guidelines, developed by Zambia’s Ministry of Health in 2025, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR), as well as the Dual Prevention Pill and oral PrEP.
